Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/Phase 2 Trial to Evaluate Safety, Immunogenicity and PSA Response of VTP-850 Prostate Cancer Immunotherapeutic in Men With Biochemical Recurrence After Definitive Local Therapy for Prostate Cancer

Trial Profile

A Phase 1/Phase 2 Trial to Evaluate Safety, Immunogenicity and PSA Response of VTP-850 Prostate Cancer Immunotherapeutic in Men With Biochemical Recurrence After Definitive Local Therapy for Prostate Cancer

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 26 Sep 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs VTP-850 (Primary) ; VTP-850 (Primary) ; Checkpoint kinase inhibitors
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Barinthus Biotherapeutics

Most Recent Events

  • 07 Aug 2025 According to Barinthus Biotherapeutics media release, this trial is now complete, with no treatment related SAEs reported. Data shows encouraging signs of immunogenicity and will be used to facilitate partnering discussions.
  • 07 May 2025 According to Barinthus Biotherapeutics media release, topline results from this study were received and analysis is ongoing.
  • 10 Jan 2025 According to Barinthus Biotherapeutics media release, results from this trial are expected in Q2 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top